Table 5.
Clinical predictors of treatment success versus death and treatment failure among children and adolescents treated for rifampicin-resistant tuberculosis stratified by age
| Clinical predictor | Treatment success versus unfavourable outcomes (death/treatment failure) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age < 5 years | Age 5 to <10 years | Age 10 to <15 years | Age 15–19 years | |||||||||||||
| Univariable logistic regression models | Multivariable logistic regression model | Univariable logistic regression models | Multivariable logistic regression model | Univariable logistic regression models | Multivariable logistic regression model | Univariable logistic regression models | Multivariable logistic regression model | |||||||||
| Crude OR (95% CI) | p-value | aOR (95% CI) | p-value | Crude OR (95% CI) | p-value | aOR (95% CI) | p-value | Crude OR (95% CI) | p-value | aOR (95% CI) | p-value | Crude OR (95% CI) | p-value | aOR (95% CI) | p-value | |
| Upper-middle or high-income country | 5.24 (0.1.5–18.3) | 0.0095 | - | - | 2.37 (0.85–6.59) | 0.097 | - | - | 1.5 (0.83–2.72) | 0.17 | - | - | 0.82 (0.55–1.22) | 0.33 | - | - |
| Age (years) | 1.16 (0.96–1.4) | 0.13 | 1.17 (0.97–1.42) | 0.11 | 0.94 (0.82–1.07) | 0.37 | 1.01 (0.87–1.16) | 0.94 | 0.90 (0.84–0.96) | 0.0025 | 0.91 (0.85–0.98) | 0.011 | 0.99 (0.95–1) | 0.37 | 0.99 (0.96–1) | 0.82 |
| Male sex | 0.87 (0.56–1.37) | 0.55 | 0.84 (0.53–1.35) | 0.47 | 1.07 (0.74–1.56) | 0.72 | 1.08 (0.73–1.59) | 0.71 | 0.75 (0.61–0.91) | 0.0045 | 0.75 (0.61–0.92) | 0.0067 | 0.86 (0.79–0.93) | 0.00038 | 0.87 (0.79–0.95) | 0.0015 |
| HIV positive | 0.29 (0.16–0.52) | <0.0001 | 0.3 (0.16–0.56) | 0.00016 | 0.34 (0.19–0.59) | 0.00013 | 0.49 (0.27–0.89) | 0.019 | 0.39 (0.29–0.53) | <0.0001 | 0.42 (0.30–0.58) | <0.0001 | 0.4 (0.34–0.47) | <0.0001 | 0.39 (0.33–0.46) | <0.0001 |
| Microbiologically confirmed tuberculosis | 0.68 (0.29–1.6) | 0.37 | - | - | 0.37 (0.17–0.81) | 0.012 | - | - | 1.32 (0.98–1.78) | 0.070 | - | - | 1.6 (1.4–1.83) | <0.0001 | - | - |
| Previous tuberculosis treatment | 0.76 (0.39–1.5) | 0.42 | 0.96 (0.47–1.94) | 0.47 | 0.51 (0.33–0.80) | 0.0036 | 0.64 (0.39–1.05) | 0.080 | 0.45 (0.36–0.57) | <0.0001 | 0.51 (0.40–0.66) | 0.011 | 0.48 (0.43–0.55) | <0.0001 | 0.51 (0.45–0.58) | <0.0001 |
| Pulmonary tuberculosis | 0.5 (0.14–1.82) | 0.30 | 0.6 (0.16–2.26) | 0.44 | 0.27 (0.08–0.96) | 0.043 | 0.30 (0.08–1.11) | 0.071 | 0.45 (0.16–1.24) | 0.45 | 0.52 (0.18–1.47) | 0.21 | 0.59 (0.36–0.96) | 0.032 | 0.53 (0.32–0.89) | 0.017 |
| Extrapulmonary tuberculosis | 1.61 (0.51–2.64) | 0.72 | - | - | 1.51 (0.75–3.04) | 0.25 | - | - | 1.84 (1.26–2.68) | 0.0019 | - | - | 1.5 (1.12–2) | 0.0081 | - | - |
| AFB smear positive | 0.33 (0.18–0.59) | 0.00022 | 0.34 (0.19–0.63) | 0.00054 | 0.31 (0.20–0.48) | <0.0001 | 0.35 (0.21–0.60) | <0.0001 | 0.47 (0.37–0.59) | <0.0001 | 0.48 (0.38–0.6) | <0.0001 | 0.47 (0.4–0.56) | <0.0001 | 0.46 (0.39–0.54) | <0.0001 |
AFB, acid-fast bacilli; OR, odds ratio; aOR, adjusted OR